Blanchard’s story begins with a diagnosis that upended the ordinary timeline of a young life. Early-stage breast cancer in adolescents and young adults is relatively uncommon, but when it occurs, it forces patients to confront questions that most people their age never have to consider. Among the most pressing is fertility. Chemotherapy, endocrine therapy and other components of modern breast cancer treatment can impair ovarian function, and for hormone receptor-positive disease, the standard of care typically includes years of endocrine therapy such as tamoxifen, during which pregnancy is generally discouraged. For a young survivor who hopes to have children, this creates a collision between two goals that feel equally urgent: protecting herself from recurrence and preserving the possibility of motherhood.

For Blanchard, that collision became concrete in the form of a decision about a therapy break. Endocrine therapy for breast cancer is usually recommended for five to ten years, and its protective effect depends on continuous adherence. Yet young survivors who want to become pregnant must often consider pausing treatment, a prospect that raises the specter of recurrence. In her account, Blanchard describes the fear that accompanied this calculus, the sense that choosing family planning might mean gambling with her own survival. That fear, she writes, shadowed every conversation with her care team and every milestone in her treatment. The emotional weight of weighing a possible cancer recurrence against a possible pregnancy is, in her telling, one of the defining burdens of young survivorship.

The clinical framework for these decisions has evolved considerably in recent years. Studies of pregnancy after breast cancer have generally been reassuring, showing that survivors who become pregnant after treatment do not appear to face a substantially elevated risk of recurrence compared with similar patients who do not become pregnant. This evidence underpins the growing practice of offering carefully supervised endocrine therapy pauses, sometimes lasting up to two years, to selected young survivors who wish to try to conceive. The strategy, studied in prospective trials, allows a window for pregnancy while monitoring closely for signs of the disease returning. But the clinical reassurance that such pauses are reasonably safe does not erase the psychological toll of making the choice, and Blanchard’s reflection makes clear that the data and the dread coexist uneasily.

What her account adds to the literature is the part that rarely appears in clinical papers: the experience of pregnancy loss after cancer. Blanchard describes a series of losses following her diagnosis, each one compounding the grief of the last and entangling itself with her cancer history. For many survivors, a miscarriage is not only the loss of a pregnancy but an occasion for self-interrogation. Did the treatment damage my eggs? Did the endocrine therapy leave my body unable to sustain a pregnancy? Did I wait too long, or act too soon? In the absence of clear information, survivors often fill the silence with blame, and Blanchard’s title, addressed to herself and to others in her position, is a direct rebuttal: this is not your fault.

The medical evidence offers some support for that reassurance, though it is incomplete. Pregnancy loss is common in the general population, with a substantial fraction of recognized pregnancies ending in miscarriage, most often because of chromosomal abnormalities in the embryo that have nothing to do with the mother’s health or history. There is no strong evidence that prior breast cancer treatment, or a supervised break from endocrine therapy, dramatically increases the risk of miscarriage, although chemotherapy can reduce ovarian reserve and some treatments can affect the uterine environment. The honest answer to a survivor asking whether her cancer caused her pregnancy loss is usually that there is no reason to believe it did, and every reason to believe the loss was the kind of random biological event that occurs in millions of pregnancies. But that answer requires someone to deliver it, and Blanchard’s piece suggests that too often, no one does.

This is where her reflection turns from memoir to advocacy. In the implications section accompanying her account, she argues that adolescent and young adult cancer survivors should be offered counseling on fertility and family planning options at the time of diagnosis, not after treatment is complete, and that this support should continue throughout treatment and survivorship. The timing matters because many fertility preservation options, such as egg or embryo freezing, are only feasible before gonadotoxic therapy begins. But the argument extends beyond preservation. Survivors need ongoing conversations about when and how to safely pursue pregnancy, what the evidence says about therapy pauses, what monitoring is appropriate during and after pregnancy, and how to interpret pregnancy losses that occur along the way. Fertility, in this framing, is not a single decision point but a thread that runs through the entire survivorship experience.

The journal’s editors treated Blanchard’s reflection as more than a personal essay. In an accompanying editor’s note, associate editors Mark Lustberg and Sarah Hannum describe how her experience prompted them to invite, independently, experts in oncofertility to review the latest evidence on fertility management in breast cancer survivors. The result is a companion scoping review by Rajput, Cathcart-Rake, Ruddy and colleagues, published in the same journal, that systematically maps the evidence base on fertility in breast cancer survivorship. The pairing is deliberate: a first-person account of what the decisions feel like, placed alongside a rigorous synthesis of what the evidence shows. Together, they model the kind of dual attention, to patient experience and to clinical data, that the authors argue survivorship care requires.

The broader context makes the stakes clear. Survival rates for early breast cancer in young women are high, which means a growing population of survivors is living for decades after treatment, entering the years in which family building would ordinarily occur. Fertility preservation referral rates remain inconsistent across cancer centers, and surveys of young survivors repeatedly find gaps in knowledge about reproductive options and lingering uncertainty about the safety of pregnancy after cancer. Meanwhile, the psychological literature documents elevated rates of anxiety, depression and reproductive grief among survivors who experience infertility or pregnancy loss, with some evidence that the distress is amplified when patients attribute the loss to their cancer or its treatment. Blanchard’s insistence that the loss was not her fault speaks directly to that attribution, which clinicians can address but often do not.

Her reflection also carries a message about identity after cancer. Blanchard continued working as a physical therapist throughout her treatment and recovery, supporting other patients recovering from cancer diagnoses, and she frames that work as part of how she made meaning of her own experience. The piece is, in the end, an argument for a kind of honesty in medicine: that survivors are served not only by protocols and survival statistics but by clinicians willing to talk about the desire for children, the fear of recurrence, the grief of loss and the guilt that patients so often carry without being told to set it down. For the young survivors who will follow her through the same terrain, her account offers both a warning about what is missing from current care and a measure of the reassurance she herself had to construct alone.

Subject of Research: Fertility, family planning and pregnancy loss after breast cancer in adolescent and young adult survivors

Article Title: This is not your fault: a reflection on cancer and pregnancy loss

Article References: This is not your fault: a reflection on cancer and pregnancy loss. (n.d.). https://doi.org/10.1007/s11764-026-02121-2

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02121-2

Keywords: breast cancer, cancer survivorship, fertility, pregnancy loss, endocrine therapy, family planning, adolescent and young adult cancer, infertility, oncofertility, recurrence fear, reproductive medicine, your